Table 3 ORs (95% CIs) for a 30% baseline biomarker increment from analyses that include data from both WHI postmenopausal HT trials

Baseline biomarker

1.21 (1.09, 1.35)^a,c

1.01 (0.89, 1.14)

0.97 (0.93, 1.00)

1.16 (1.03, 1.31)^c

1.03 (0.99, 1.08)

Treatment^b

1.32 (0.97, 1.81)

1.33 (0.97, 1.81)

1.34 (0.96, 1.87)

1.31 (0.95, 1.78)

1.29 (0.94, 1.77)

Trial^b

1.13 (0.82, 1.56)

1.09 (0.79, 1.51)

1.02 (0.72, 1.44)

1.09 (0.79, 1.50)

1.05 (0.76, 1.47)

Stroke

B2M

IGFBP2

IGFBP4

IGFBP6

HPX

Baseline biomarker

1.18 (1.04, 1.34)^a,c

1.10 (1.03, 1.18)^c

1.16 (1.04, 1.28)^c

1.01 (0.94, 1.09)

1.10 (0.95, 1.27)

Treatment^b

1.90 (1.38, 2.62)

1.77 (1.27, 2.46)

1.76 (1.21, 2.54)

1.70 (1.22, 2.38)

1.79 (1.30, 2.48)

Trial^b

1.09 (0.79, 1.50)

1.10 (0.79, 1.53)

1.09 (0.75, 1.59)

1.11 (0.79, 1.55)

1.13 (0.81, 1.56)